Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Hongyan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China; Research Center of Clinical Epidemiolo…. Hauptthemen laut MEDLINE: Cathepsin K, Pituitary Neoplasms, Adenoma, Osteogenesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
This study aimed to investigate the regulation and underlying mechanism of Cathepsin K (CTSK) in bone-invasive pituitary adenomas (BIPAs). A total of 1437 patients with pituitary adenomas were included and followed up. RNA sequencing, immunohistochemistry, and qRT-PCR were used to analyze CTSK expression. The effects of CTSK on cellular proliferation, bone matrix degradation, and osteoclast differentiation were determined by gain/loss of function experiments in vitro and in vivo. The exploration of signaling pathways was determined through molecular biology experiments. Here, we reported a significant fraction (∼10 %) of pituitary adenoma patients developed bone invasion, which was correlated with tumor recurrence. Patients with BIPAs had shorter recurrence-free survival. CTSK expression was increased in BIPA patients and was strongly associated with a worse prognosis. Increased CTSK expression enhanced pituitary adenoma cell proliferation through the activation of the mammalian target of rapamycin (mTOR) signaling pathway and promoted bone invasion by increasing osteoclast differentiation both in vitro and in vivo. Treatment with the CTSK inhibitor odanacatib effectively inhibited pituitary adenoma cell proliferation and bone invasion in these models. Additionally, CTSK facilitated osteoclast differentiation by promoting RANKL expression in MC3T3-E1 cells via interaction with TLR4. Based on these findings, we conclude that CTSK has the potential to become a novel predictive biomarker and therapeutic target for BIPAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China; Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China.
- Department of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
- Department of Pathology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
- Department of Endocrinology, The 908th Hospital of Chinese PLA Joint Logistic Support Force, Nanchang, China.
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. Electronic address: muyiming@301hospital.com.
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. Electronic address: guweijun@301hospital.com.cn.
Zitieren
APA
Liu, H., Wang, P., Li, J., Zhao, J., Mu, Y., & Gu, W. (2025). Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217443
Vancouver
Liu H, Wang P, Li J, Zhao J, Mu Y, Gu W. Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217443
BibTeX
@article{Liu2025,
author = {Liu, Hongyan and Wang, Peng and Li, Jie and Zhao, Jian and Mu, Yiming and Gu, Weijun},
title = {Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217443}
}
EUVIMED